DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more
DNA Biomed Solns (DNA) - Net Assets
Latest net assets as of June 2025: ILA98.23 Million ILA
Based on the latest financial reports, DNA Biomed Solns (DNA) has net assets worth ILA98.23 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA100.00 Million) and total liabilities (ILA1.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA98.23 Million |
| % of Total Assets | 98.23% |
| Annual Growth Rate | 19.84% |
| 5-Year Change | 1176.13% |
| 10-Year Change | N/A |
| Growth Volatility | 501.04 |
DNA Biomed Solns - Net Assets Trend (2005–2024)
This chart illustrates how DNA Biomed Solns's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DNA Biomed Solns (2005–2024)
The table below shows the annual net assets of DNA Biomed Solns from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA101.47 Million | +28.13% |
| 2023-12-31 | ILA79.19 Million | -1.15% |
| 2022-12-31 | ILA80.11 Million | +47.44% |
| 2021-12-31 | ILA54.33 Million | +583.32% |
| 2020-12-31 | ILA7.95 Million | -71.79% |
| 2019-12-31 | ILA28.18 Million | -56.58% |
| 2018-12-31 | ILA64.90 Million | -6.08% |
| 2017-12-31 | ILA69.11 Million | +182.85% |
| 2016-12-31 | ILA-83.41 Million | -899.20% |
| 2015-12-31 | ILA-8.35 Million | +0.11% |
| 2014-12-31 | ILA-8.36 Million | -172.73% |
| 2013-12-31 | ILA11.49 Million | -0.30% |
| 2012-12-31 | ILA11.53 Million | +10.28% |
| 2011-12-31 | ILA10.45 Million | +1705.01% |
| 2010-12-31 | ILA579.00K | +108.80% |
| 2009-12-31 | ILA-6.58 Million | -119.37% |
| 2008-12-31 | ILA-3.00 Million | -50.48% |
| 2006-12-31 | ILA-1.99 Million | -161.21% |
| 2005-12-31 | ILA3.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DNA Biomed Solns's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5144100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA152.91 Million | 150.70% |
| Total Equity | ILA101.47 Million | 100.00% |
DNA Biomed Solns Competitors by Market Cap
The table below lists competitors of DNA Biomed Solns ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TRACTOR SUPPLY (TR4.SG)
STU:TR4
|
$393.03K |
|
Formuepleje Mix Medium
CO:FPIMME
|
$393.43K |
|
BEKAERT - Dusseldorf Stock Exchang
DU:BK8N
|
$394.12K |
|
SAS AB (publ)
PINK:SASBQ
|
$395.16K |
|
NANOSPHERE
F:3NS
|
$392.71K |
|
NWMX
BATS:NWMX
|
$391.92K |
|
Samwha Capacitor Co. Ltd.
KQ:001820
|
$391.80K |
|
CIMPRESS (7VP.SG)
STU:7VP
|
$391.78K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DNA Biomed Solns's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 79,187,000 to 101,465,000, a change of 22,278,000 (28.1%).
- Net income of 22,096,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA22.10 Million | +21.78% |
| Other Changes | ILA182.00K | +0.18% |
| Total Change | ILA- | 28.13% |
Book Value vs Market Value Analysis
This analysis compares DNA Biomed Solns's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 124.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 36.60x to 124.78x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA2.81 | ILA102.80 | x |
| 2018-12-31 | ILA2.64 | ILA102.80 | x |
| 2019-12-31 | ILA0.93 | ILA102.80 | x |
| 2020-12-31 | ILA0.26 | ILA102.80 | x |
| 2021-12-31 | ILA0.54 | ILA102.80 | x |
| 2022-12-31 | ILA0.65 | ILA102.80 | x |
| 2023-12-31 | ILA0.64 | ILA102.80 | x |
| 2024-12-31 | ILA0.82 | ILA102.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DNA Biomed Solns utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7220.92%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (21.78%) is above the historical average (-15.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -18.27% | 0.00% | 0.00x | 2.06x | ILA-2.83 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-65.57 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-9.60 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | ILA2.39 Million |
| 2017 | 213.23% | 0.00% | 0.00x | 1.13x | ILA140.45 Million |
| 2018 | -22.01% | 0.00% | 0.00x | 1.24x | ILA-20.78 Million |
| 2019 | -136.72% | 0.00% | 0.00x | 1.30x | ILA-41.35 Million |
| 2020 | -242.30% | 0.00% | 0.00x | 2.33x | ILA-20.06 Million |
| 2021 | 33.82% | 0.00% | 0.00x | 1.01x | ILA12.94 Million |
| 2022 | -29.38% | -4202.86% | 0.01x | 1.02x | ILA-31.55 Million |
| 2023 | -1.49% | -384.64% | 0.00x | 1.02x | ILA-9.10 Million |
| 2024 | 21.78% | 7220.92% | 0.00x | 1.03x | ILA11.95 Million |
Industry Comparison
This section compares DNA Biomed Solns's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $171,657,375
- Average return on equity (ROE) among peers: -71.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DNA Biomed Solns (DNA) | ILA98.23 Million | -18.27% | 0.02x | $392.94K |
| BioLine RX Ltd (BLRX) | $22.03 Million | -140.41% | 1.15x | $104.99K |
| BioLight Life Sciences Ltd (BOLT) | $60.11 Million | -22.26% | 0.08x | $82.11K |
| Can Fite Biopharma Ltd (CANF) | $4.47 Million | -227.48% | 1.08x | $137.32K |
| Clal Biotechnology Industries Ltd (CBI) | $1.11 Billion | 7.88% | 0.13x | $130.78K |
| G.F.C Green Fields Capital Ltd. (GFC-M) | $134.15 Million | 1.81% | 0.56x | $402.34K |
| Matricelf Ltd (MTLF) | $35.79 Million | -34.88% | 0.10x | $388.41K |
| Plantarc Bio Ltd (PLNT) | $3.29 Million | -65.33% | 0.19x | $19.61K |
| XTL Biopharmaceuticals Ltd (XTLB) | $4.89 Million | -88.25% | 0.09x | $68.53K |